Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-BV
- Development stage
- Unknown
- Lead developer
- University of Tokyo
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
T-BV is a third-generation oncolytic herpes simplex virus type 1 (HSV-1) genetically engineered to express bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF). Developed by the University of Tokyo in collaboration with the Japan Agency for Medical Research and Development (AMED), T-BV is designed to treat malignant gliomas. It functions through a dual mechanism: direct oncolysis, where the virus selectively replicates in and destroys cancer cells, and anti-angiogenesis, where the locally produced bevacizumab inhibits the formation of new blood vessels that support tumor growth. This localized expression is intended to enhance therapeutic efficacy while reducing the systemic side effects associated with intravenous bevacizumab. It is currently being evaluated in Phase I clinical trials for recurrent or progressive malignant glioma.
- Other names
- bevacizumab-expressing oncolytic herpesvirus
02
Targets
Beyond the preview
Go deeper on T-BV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-BV.